Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05633966 · ClinicalTrials.gov registry record · Phase 1
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
A Phase 1 study, sponsored by Stephanie B. Seminara, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT05633966 is a Phase 1 study that has completed, run by Stephanie B. Seminara, MD. The registered enrollment target is 13 participants.
The verdict
NCT05633966, a Phase 1 study, has completed, sponsored by Stephanie B. Seminara, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.
Interventions
- DRUG Kisspeptin 112-121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2025-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05633966
The ClinicalTrials.gov registry entry for NCT05633966 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stephanie B. Seminara, MD, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kisspeptin 112-121 is the first listed.
NCT05633966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05633966 about?
NCT05633966 is a clinical study titled "Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders". The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin ...
What is the current status of trial NCT05633966?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2022-12-16. Estimated completion is 2025-08-31.
What interventions are being tested in trial NCT05633966?
The interventions under investigation include: Kisspeptin 112-121 (DRUG).
Who is sponsoring clinical trial NCT05633966?
This trial is sponsored by Stephanie B. Seminara, MD, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.